CA2296080A1 - Ophthalmic compositions containing galactomannan polymers and borate - Google Patents

Ophthalmic compositions containing galactomannan polymers and borate Download PDF

Info

Publication number
CA2296080A1
CA2296080A1 CA002296080A CA2296080A CA2296080A1 CA 2296080 A1 CA2296080 A1 CA 2296080A1 CA 002296080 A CA002296080 A CA 002296080A CA 2296080 A CA2296080 A CA 2296080A CA 2296080 A1 CA2296080 A1 CA 2296080A1
Authority
CA
Canada
Prior art keywords
compositions containing
borate
ophthalmic compositions
galactomannan polymers
containing galactomannan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002296080A
Other languages
French (fr)
Other versions
CA2296080C (en
Inventor
Bahram Asgharian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Vision LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21988983&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2296080(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2296080A1 publication Critical patent/CA2296080A1/en
Application granted granted Critical
Publication of CA2296080C publication Critical patent/CA2296080C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/22—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/08—Mydriatics or cycloplegics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

The present invention is directed to ophthalmic compositions containing a gelling amount of a combination of galactomannan polysaccharides and borates. The compositions gel or partially gel upon administration to the eye. The present invention also discloses methods of topical ophthalmic administration of the compositions of the eye.
CA002296080A 1997-07-29 1998-07-17 Ophthalmic compositions containing galactomannan polymers and borate Expired - Lifetime CA2296080C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5413297P 1997-07-29 1997-07-29
US60/054,132 1997-07-29
PCT/US1998/014596 WO1999006023A1 (en) 1997-07-29 1998-07-17 Ophthalmic compositions containing galactomannan polymers and borate

Publications (2)

Publication Number Publication Date
CA2296080A1 true CA2296080A1 (en) 1999-02-11
CA2296080C CA2296080C (en) 2005-02-01

Family

ID=21988983

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002296080A Expired - Lifetime CA2296080C (en) 1997-07-29 1998-07-17 Ophthalmic compositions containing galactomannan polymers and borate

Country Status (20)

Country Link
US (6) US6403609B1 (en)
EP (2) EP0999825B1 (en)
JP (2) JP3979783B2 (en)
KR (1) KR100507984B1 (en)
CN (3) CN100408100C (en)
AR (1) AR013272A1 (en)
AT (2) ATE250923T1 (en)
AU (1) AU737442B2 (en)
BR (1) BR9811574B1 (en)
CA (1) CA2296080C (en)
CY (2) CY1110365T1 (en)
DE (2) DE69839355T2 (en)
DK (2) DK0999825T3 (en)
ES (2) ES2302881T3 (en)
HK (2) HK1026618A1 (en)
LU (1) LU92301I2 (en)
PT (2) PT1348427E (en)
TW (2) TWI233801B (en)
WO (1) WO1999006023A1 (en)
ZA (1) ZA986533B (en)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872710B2 (en) * 1997-07-25 2005-03-29 Inspire Pharmaceuticals, Inc. Di(uridine 5′)-tetraphosphate and salts thereof
EP0999825B1 (en) 1997-07-29 2003-10-01 Alcon Laboratories, Inc. Ophthalmic compositions containing galactomannan polymers and borate
JP3361106B2 (en) 1997-07-29 2003-01-07 アルコン ラボラトリーズ，インコーポレイテッド Conditioning solution for hard contact lens care
KR20070087252A (en) * 2000-12-20 2007-08-27 알콘, 인코퍼레이티드 Intraocular irrigating solution having improved flow characteristics
WO2002049611A2 (en) 2000-12-20 2002-06-27 Alcon, Inc. Ophthalmic lubricating solution adapted for use in lasik surgery
US7169755B2 (en) 2000-12-20 2007-01-30 Alcon, Inc. Solution for removing cataracts via liquefracture
WO2002049610A2 (en) 2000-12-20 2002-06-27 Alcon, Inc. Ophthalmic irrigating solution adapted for use in lasik surgery
US7084130B2 (en) * 2001-12-11 2006-08-01 Alcon, Inc. Intraocular irrigating solution having improved flow characteristics
US20090258955A1 (en) * 2000-12-20 2009-10-15 Alcon, Inc. Intraocular irrigating solution having improved flow characteristics
US6844296B2 (en) * 2001-06-22 2005-01-18 Bj Services Company Fracturing fluids and methods of making and using same
FR2832223B1 (en) 2001-11-15 2005-01-14 Cit Alcatel MULTISECTION ELECTRO-OPTIC MONOLITHIC COMPONENT
EP1455804A4 (en) * 2001-12-21 2005-01-05 Alcon Inc Use of nanoparticles as carriers for biocides in ophthalmic compositions
BR0215149A (en) * 2001-12-21 2004-10-19 Alcon Inc Use of inorganic nanoparticles to modify viscosity and other physical properties of pharmaceutical and optical compositions.
PL211494B1 (en) * 2001-12-21 2012-05-31 Alcon Use of synthetic inorganic nanoparticles as carriers for ophthalmic and otic drugs
CA2477044A1 (en) * 2002-02-22 2003-09-04 Pharmacia Corporation Ophthalmic formulation with gum system
AU2003263753A1 (en) 2002-06-25 2004-01-06 Rhodia, Inc. Molecular weight reduction of polysaccharides by electron beams
RU2325405C2 (en) * 2002-06-25 2008-05-27 Родиа, Инк. Guar graph-interpolymerization and other polysaccharides by electron-beam machining
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US8877168B1 (en) 2002-07-31 2014-11-04 Senju Pharmaceuticals Co., Ltd. Aqueous liquid preparations and light-stabilized aqueous liquid preparations
ATE528003T1 (en) * 2002-07-31 2011-10-15 Senju Pharma Co AQUEOUS, LIQUID PREPARATIONS AND LIGHT-STABILIZED AQUEOUS LIQUID PREPARATIONS
JP4865330B2 (en) 2002-12-13 2012-02-01 デュレクト コーポレーション Oral drug delivery system
TWI336257B (en) * 2003-06-13 2011-01-21 Alcon Inc Ophthalmic compositions containing a synergistic combination of three polymers
AU2012205283B2 (en) * 2003-06-13 2014-08-07 Alcon, Inc. Ophthalmic compositions containing a synergistic combination of two polymers
US7947295B2 (en) * 2003-06-13 2011-05-24 Alcon, Inc. Ophthalmic compositions containing a synergistic combination of two polymers
US7914803B2 (en) 2003-06-13 2011-03-29 Alcon, Inc. Ophthalmic compositions containing a synergistic combination of three polymers
AU2004249137B2 (en) * 2003-06-13 2010-03-11 Alcon, Inc. Ophthalmic compositions containing a synergistic combination of two polymers
US20050129770A1 (en) * 2003-12-11 2005-06-16 Alcon, Inc. Ophthalmic compositions containing a PVA/borate gelling system
CA2545947A1 (en) * 2003-12-11 2005-07-07 Alcon, Inc. Ophthalmic compositions containing a polysaccharide/borate gelling system
US20050137166A1 (en) * 2003-12-19 2005-06-23 Alcon, Inc. Use of cooling agents to relieve mild ocular irritation and enhance comfort
JP2007524690A (en) * 2004-02-17 2007-08-30 ヴェーリ・インター・アーゲー Galactomannan and / or glucomannan for enhancing the bioavailability of active substances
WO2005089755A1 (en) * 2004-03-18 2005-09-29 R-Tech Ueno, Ltd. Aqueous composition comprising thiazole derivative
US7022740B2 (en) * 2004-04-29 2006-04-04 Leonard Mackles Lubricious ophthalmic solutions
KR100665299B1 (en) * 2004-06-10 2007-01-04 서울반도체 주식회사 Luminescent material
ES2368842T3 (en) * 2004-08-03 2011-11-22 Rhodia, Inc. COPYLIMERS OF POLYSACARIDE GRAFT AND ITS USE IN APPLICATIONS FOR HAIR CARE.
JP4771044B2 (en) * 2004-09-15 2011-09-14 大正製薬株式会社 Mucosal fluid
PT2767292T (en) * 2004-09-17 2016-11-23 Durect Corp Sustained local anesthetic composition containing saib
US20070059274A1 (en) * 2004-12-01 2007-03-15 Bahram Asgharian Ophthalmic compositions containing a PVA/borate gelling system
US8318210B2 (en) 2005-02-28 2012-11-27 Neos Therapeutics, Lp Compositions and methods of making sustained release liquid formulations
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US20070048338A1 (en) * 2005-08-26 2007-03-01 Ladd Byron S Compositions and methods for surface treatment in medical and surgical procedures
US20100130580A1 (en) * 2006-01-25 2010-05-27 Aciex Therapeutics, Inc. Formulations and Methods for Treating Dry Eye
EP1981491A4 (en) * 2006-01-25 2009-09-23 Aciex Inc Formulations and methods for treating dry eye
EP2035015A4 (en) * 2006-05-01 2009-11-11 Riolan Technologies Inc Compositions, methods, and kits for treating dry eye
US20100021561A1 (en) * 2006-09-21 2010-01-28 Chowhan Masood A Self-preserved aqueous pharmaceutical compositions
TWI394564B (en) * 2006-09-21 2013-05-01 Alcon Res Ltd Self-preserved aqueous pharmaceutical compositions
US8388941B2 (en) * 2006-09-28 2013-03-05 Alcon Research, Ltd. Self preserved aqueous pharmaceutical compositions
ES2388355T3 (en) 2006-11-03 2012-10-11 Durect Corporation Transdemic delivery systems comprising bupivacaine
AU2007343701B2 (en) * 2007-01-16 2013-01-31 Texas Tech University System Method and apparatus for gender selection based on pH
AU2008216497B2 (en) * 2007-02-09 2013-09-26 Alcon, Inc. Ophthalmic compositions containing a synergistic combination of three polymers
WO2008112163A1 (en) * 2007-03-09 2008-09-18 Corning Incorporated Gum coatings for cell culture, methods of manufacture and methods of use
JP2010520766A (en) * 2007-03-09 2010-06-17 コーニング インコーポレイテッド Three-dimensional gum matrix for cell culture, production method and method of use
EP2160182A1 (en) * 2007-05-24 2010-03-10 Aciex Therapeutics, Inc. Formulations and methods for treating dry eye
US20090131303A1 (en) * 2007-11-16 2009-05-21 Bor-Shyue Hong Methods and compositions for treating dry eye
WO2009088414A2 (en) 2007-12-06 2009-07-16 Durect Corporation Oral pharmaceutical dosage forms
US7795316B1 (en) 2007-12-19 2010-09-14 Alcon Research, Ltd. Topical ophthalmic compositions containing tobramycin and dexamethasone
CN101959500A (en) * 2008-03-17 2011-01-26 爱尔康研究有限公司 Aqueous pharmaceutical compositions containing borate-polyol complexes
US20090270345A1 (en) * 2008-04-26 2009-10-29 Alcon Research, Ltd. Polymeric artificial tear system
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
CA2749809C (en) * 2009-02-05 2017-03-14 Alcon Research, Ltd. Process for purifying guar
TW201039815A (en) 2009-04-13 2010-11-16 Resolvyx Pharmaceuticals Inc Compositions and methods for the treatment of inflammation
TWI489997B (en) 2009-06-19 2015-07-01 Alcon Res Ltd Aqueous pharmaceutical compositions containing borate-polyol complexes
TWI547522B (en) * 2009-07-07 2016-09-01 愛爾康研究有限公司 Ethyleneoxide butyleneoxide block copolymer compositions
EP2586426B1 (en) 2009-12-03 2015-09-23 Alcon Research, Ltd. Carboxyvinyl polymer-containing nanoparticle suspensions
TWI478730B (en) 2009-12-03 2015-04-01 Alcon Res Ltd Ophthalmic emulsion
MX2012012826A (en) * 2010-05-05 2013-01-28 Alcon Res Ltd Stabilized ophthalmic galactomannan formulations.
BR112012033052A2 (en) * 2010-06-23 2019-09-24 Alcon Res Ltd topical ophthalmic suspensions containing tobramicin and dexamethasone
DK2632927T3 (en) 2010-10-26 2016-04-11 Mars Inc Boronates AS ARGINSASEINHIBITORER
WO2012145470A2 (en) 2011-04-22 2012-10-26 Alcon Research, Ltd. Ophthalmic composition with a viscosity enhancement system having two different viscosity enhancing agents
KR20140022900A (en) 2011-04-22 2014-02-25 알콘 리서치, 리미티드 Ophthalmic composition with a viscosity enhancement system having two different viscosity enhancing agents
CA2856386C (en) 2011-11-21 2022-05-31 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
TW201336527A (en) * 2012-02-10 2013-09-16 Alcon Res Ltd Aqueous pharmaceutical composition with enhanced stability
UA113434C2 (en) 2012-05-04 2017-01-25 Алкон Рісерч, Лтд. Ophthalmic compositions with improved dessication protection and retention
CN102860949B (en) * 2012-08-31 2014-07-02 马应龙药业集团股份有限公司 Anti-wrinkle skin-care product for eyes and preparation method for anti-wrinkle skin-care product
PL2920168T3 (en) 2012-11-16 2022-01-03 Calithera Biosciences, Inc. Heterocyclic glutaminase inhibitors
US9572885B2 (en) 2013-03-15 2017-02-21 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
EP3013790A1 (en) 2013-06-27 2016-05-04 Mylan Laboratories Ltd. Process for the preparation of nepafenac
US10350161B2 (en) 2013-10-15 2019-07-16 Pharmathen S.A. Preservative free pharmaceutical compositions for ophthalmic administration
FR3000391B3 (en) 2013-11-12 2015-02-20 Pharmathen Sa NON-CONSERVATIVE PHARMACEUTICAL COMPOSITIONS FOR OPHTHALMIC ADMINISTRATION
CN103572651B (en) * 2013-11-25 2016-05-04 齐鲁工业大学 A kind of modification tara gum and preparation method thereof and application
CA2978874C (en) * 2014-03-17 2023-08-29 Encompass Development, Inc. Ocular formulations comprising a glycosaminoglycan and an anesthetic
AU2015274361B2 (en) 2014-06-13 2020-11-05 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
EP3193876B1 (en) 2014-08-07 2022-01-12 Calithera Biosciences Inc. Crystal forms of glutaminase inhibitors
EP3180332B1 (en) 2014-08-13 2021-10-27 Eolas Therapeutics Inc. Difluoropyrrolidines as orexin receptor modulators
US20170368192A1 (en) 2014-10-13 2017-12-28 Symic Ip, Llc Luminal vessel coating for arteriovenous fistula
WO2016061145A1 (en) 2014-10-13 2016-04-21 Symic Biomedical, Inc. Synthetic proteoglycans for preventing tissue adhesion
WO2016065083A1 (en) 2014-10-21 2016-04-28 Symic Biomedical, Inc. Peptidoglycans comprising collagen-binding peptides for treating gastroesophageal injury
SG10202108921VA (en) 2015-03-10 2021-09-29 Aurigene Discovery Tech Ltd 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
CA2990192A1 (en) 2015-06-23 2016-12-29 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
US20170037303A1 (en) 2015-08-03 2017-02-09 Ecolab Usa Inc. Compositions and methods for delayed crosslinking in hydraulic fracturing fluids
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
CA3000996A1 (en) 2015-10-05 2017-04-13 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors and immuno-oncology agents
TW201718028A (en) 2015-10-13 2017-06-01 賽米克Ｉｐ有限責任公司 VE-Cadherin binding bioconjugate
CA3002384C (en) * 2015-10-25 2021-02-16 Iview Therapeutics, Inc. Pharmaceutical formulations that form gel in situ
TWI710565B (en) 2015-10-30 2020-11-21 美商卡利泰拉生物科技公司 Compositions and methods for inhibiting arginase activity
CA3005444A1 (en) 2015-11-16 2017-05-26 Ichorion Therapeutics, Inc. Nucleic acid prodrugs
JP6703408B2 (en) * 2016-01-30 2020-06-03 国立大学法人 筑波大学 Composition for treating dry eye containing polyion complex as active ingredient
JP6883045B2 (en) 2016-02-12 2021-06-02 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Halo-substituted piperidine as an orexin receptor regulator
US10087363B2 (en) * 2016-03-15 2018-10-02 Baker Hughes, A Ge Company, Llc Using borated galactomannan to enhance swelling of superabsorbents for fracturing applications
US10793590B2 (en) 2016-06-03 2020-10-06 President And Fellows Of Harvard College Antifungal compounds
US10550315B2 (en) 2016-07-15 2020-02-04 Ecolab Usa Inc. Compositions and methods for delayed crosslinking in hydraulic fracturing fluids
US10472364B2 (en) 2016-09-09 2019-11-12 Calithera Biosciences, Inc. Ectonucleotidase inhibitors and methods of use thereof
EP3509583B1 (en) 2016-09-09 2021-06-30 The Regents of the University of California Estrogen receptor ligands, compositions and methods related thereto
EP3512834A4 (en) 2016-09-14 2020-05-06 Vanderbilt University Inhibition of bmp signaling, compounds, compositions and uses thereof
CA3034652A1 (en) 2016-09-26 2018-03-29 Dana-Farber Cancer Institute, Inc. Chromobox protein inhibitors and uses thereof
CN110352063A (en) 2016-11-08 2019-10-18 卡里塞拉生物科学股份公司 Arginase inhibitor combination treatment
AU2017382405B2 (en) 2016-12-22 2021-12-16 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
CN110430880A (en) 2017-01-18 2019-11-08 范德比尔特大学 The alternatively condensed heterocyclic compouds of property BMP inhibitor
KR20190120786A (en) 2017-02-24 2019-10-24 메르크 파텐트 게엠베하 1,4,6-trisubstituted-2-alkyl-1H-benzo [d] imidazole derivatives as dihydroorotate oxygenase inhibitors
IL293783B2 (en) 2017-03-31 2024-01-01 Aurigene Oncology Ltd Compounds and compositions for treating hematological disorders
WO2018209288A1 (en) 2017-05-12 2018-11-15 Massachusetts Institute Of Technology Argonaute protein-double stranded rna complexes and uses related thereto
US11325943B2 (en) 2017-06-02 2022-05-10 Stealth Biotherapeutics Inc. Crystalline salt forms of SBT-20
WO2019018539A1 (en) 2017-07-19 2019-01-24 California Institute Of Technology Methods for preparing bis-tetrahydroisoquinoline-containing compounds
WO2019073399A1 (en) 2017-10-11 2019-04-18 Aurigene Discovery Technologies Limited Crystalline forms of 3-substituted 1,2,4-oxadiazole
EP4234037A3 (en) 2017-10-19 2023-09-06 Signpath Pharma, Inc. Liquid compositions for peroral use comprising phosphatidylglycerol derivatives and thixotropic excipients for treating cardiac channelopathies caused by pharmacological agents
EA202090497A1 (en) 2017-10-31 2020-11-23 Кьюрис, Инк. COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF HEMATOLOGICAL DISORDERS
BR112020008537A2 (en) 2017-11-03 2020-10-06 Aurigene Discovery Technologies Limited dual tim-3 and pd-1 pathway inhibitors
AU2018360389A1 (en) 2017-11-06 2020-05-07 Aurigene Oncology Limited Conjoint therapies for immunomodulation
RU2020124097A (en) 2017-12-22 2022-01-24 Медиммьюн Лимитед LOW-MOLECULAR MODULATORS OF THE BTB Keap1 DOMAIN
TW201938141A (en) 2018-02-21 2019-10-01 瑞士商諾華公司 Lipid- based ophthalmic emulsion
US10745400B2 (en) 2018-03-14 2020-08-18 Vanderbuilt University Inhibition of BMP signaling, compounds, compositions and uses thereof
AU2019310595B2 (en) 2018-07-27 2022-11-24 1200 Pharma Llc CDK inhibitors and uses thereof
CN110787126A (en) * 2018-08-03 2020-02-14 武汉武药科技有限公司 Moxifloxacin hydrochloride ophthalmic gel and preparation method thereof
AU2019336698A1 (en) 2018-09-05 2021-03-25 Aztherapies, Inc. Methods of treating cytokine release syndrome
WO2020086963A1 (en) 2018-10-26 2020-04-30 Keros Therapeutics Crystal forms of an alk2 inhibitor
CA3122989A1 (en) 2018-12-10 2020-06-18 The General Hospital Corporation Cromolyn esters and uses thereof
CN113574055A (en) 2019-01-18 2021-10-29 阿斯利康(瑞典)有限公司 PCSK9 inhibitors and methods of use thereof
CA3131753A1 (en) 2019-03-14 2020-09-17 Astrazeneca Ab Lanabecestat for weight loss
WO2020246503A1 (en) 2019-06-03 2020-12-10 株式会社大分大学先端医学研究所 Cyclic amide compounds for rabies treatment and method thereof
TWI757773B (en) * 2019-06-28 2022-03-11 瑞士商愛爾康公司 Ophthalmic compositions
CN114727954A (en) * 2019-09-18 2022-07-08 爱尔康公司 Wet packed soft hydrogel ocular inserts
AU2020382827A1 (en) 2019-11-12 2022-05-26 Genzyme Corporation 6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient CFTR activity
WO2021113809A1 (en) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides and methods of use thereof
WO2021113806A1 (en) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides and methods of use thereof
WO2021125800A1 (en) 2019-12-16 2021-06-24 울산과학기술원 Compound for inhibiting angiogenesis factor, and use thereof
CN115666621A (en) 2020-01-13 2023-01-31 度勒科特公司 Sustained release drug delivery systems with reduced impurities and related methods
AU2022257621A1 (en) 2021-04-13 2023-11-23 Nuvalent, Inc. Amino-substituted heterocycles for treating cancers with egfr mutations
CA3230259A1 (en) 2021-09-03 2023-03-09 Junkai Liao Indole compounds and methods of use
WO2023034946A1 (en) 2021-09-03 2023-03-09 Genzyme Corporation Indole compounds and uses thereof in the treatement of cystic fibrosis
CA3231608A1 (en) 2021-10-01 2023-04-06 Amit M. Deshpande Methods of treating solid tumor using heteroaromatic macrocyclic ether compounds
CA3231813A1 (en) 2021-10-01 2023-04-06 Sibao CHEN Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
CN114191378A (en) * 2021-11-23 2022-03-18 温州医科大学附属眼视光医院 Diquafosol sustained-release gel and preparation method and application thereof
US20230310615A1 (en) 2022-03-31 2023-10-05 Alcon Inc. Ophthalmic compositions
WO2023196910A1 (en) 2022-04-07 2023-10-12 Nuvalent, Inc Methods of treating solid tumor using (19r)-5-chloro-3-ethyl-16-fluoro-10,19-dimethyl-20-oxa-3,4,10,11,23-pentaazapentacyclo[19.3.1.02,6.08,12.013,18]pentacosa-1(24),2(6),4,8,11,13,15,17,21(25),22-decaen-22-amine
TW202400608A (en) 2022-04-07 2024-01-01 美商努法倫特公司 Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
WO2023224961A1 (en) 2022-05-16 2023-11-23 Exelixis, Inc. Cancer therapy using a combination of a cdk7 inhibitor with an oral serd
WO2024036098A1 (en) 2022-08-12 2024-02-15 Nuvalent, Inc. Heteroaromatic macrocyclic ether compounds
WO2024036097A1 (en) 2022-08-12 2024-02-15 Nuvalent, Inc. Heteroaromatic macrocyclic ether compounds and isotopologues thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3944427A (en) * 1970-04-06 1976-03-16 Itek Corporation Gelable and gelled compositions
US3843782A (en) 1971-07-26 1974-10-22 Flow Pharma Inc Eye solution and method of using same
US4136177A (en) * 1977-01-31 1979-01-23 American Home Products Corp. Xanthan gum therapeutic compositions
US4136178A (en) * 1977-01-31 1979-01-23 American Home Products Corp. Locust bean gum therapeutic compositions
US4136173A (en) 1977-01-31 1979-01-23 American Home Products Corp. Mixed xanthan gum and locust beam gum therapeutic compositions
US4255415A (en) 1978-11-22 1981-03-10 Schering Corporation Polyvinyl alcohol ophthalmic gel
US4370325A (en) 1979-03-30 1983-01-25 Dermik Laboratories Pharmaceutical compositions and method of treatment
US4436730A (en) 1979-06-25 1984-03-13 Polymer Technology Corporation Ionic opthalmic cellulose polymer solutions
US4624868A (en) * 1979-12-17 1986-11-25 Colgate-Palmolive Company Borated polysaccharide absorbents and absorbent products
US4323467A (en) 1980-11-24 1982-04-06 Syntex (U.S.A.) Inc. Contact lens cleaning, storing and wetting solutions
JPS57186733A (en) 1981-05-13 1982-11-17 Toyo Contact Lens Co Ltd Agent for use in contact lenses
US4362781A (en) * 1981-09-21 1982-12-07 Scott Paper Company Flushable premoistened wiper
US4474751A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
FR2588189B1 (en) 1985-10-03 1988-12-02 Merck Sharp & Dohme LIQUID-GEL PHASE TRANSITION PHARMACEUTICAL COMPOSITION
US5457093A (en) 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
US5188826A (en) 1988-02-08 1993-02-23 Insite Vision Incorporated Topical ophthalmic suspensions
US5192535A (en) 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
US5607698A (en) 1988-08-04 1997-03-04 Ciba-Geigy Corporation Method of preserving ophthalmic solution and compositions therefor
US5126141A (en) 1988-11-16 1992-06-30 Mediventures Incorporated Composition and method for post-surgical adhesion reduction with thermo-irreversible gels of polyoxyalkylene polymers and ionic polysaccharides
EP0386960A3 (en) 1989-03-07 1991-10-23 American Cyanamid Company Pharmaceutical compositions useful as drug delivery vehicles and/or as wound dressings
US5145590A (en) 1990-01-16 1992-09-08 Bj Services Company Method for improving the high temperature gel stability of borated galactomannans
US5082579A (en) 1990-01-16 1992-01-21 Bj Services Company Method and composition for delaying the gellation of borated galactomannans
US5160643A (en) * 1990-01-16 1992-11-03 Bj Services Company Method for delaying the gellation of borated galactomannans with a delay additive such as glyoxal
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
US5346703A (en) 1990-08-07 1994-09-13 Mediventures, Inc. Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
US5376693A (en) 1990-08-07 1994-12-27 Mediventures Inc. Thermo-irreversible gel corneal contact lens formed in situ
US5318780A (en) 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
US5922340A (en) 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
US5372732A (en) 1992-10-21 1994-12-13 Halliburton Company Delayed release borate crosslinking agent
WO1994010976A1 (en) 1992-11-16 1994-05-26 Ciba Vision Ag, Hettlingen Polyvinyl alcohol/borate ophthalmic drug delivery system
JPH06345653A (en) 1993-06-08 1994-12-20 Asahi Chem Ind Co Ltd Eye lotion
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5603929A (en) 1994-11-16 1997-02-18 Alcon Laboratories, Inc. Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds
US5972326A (en) 1995-04-18 1999-10-26 Galin; Miles A. Controlled release of pharmaceuticals in the anterior chamber of the eye
IT1283911B1 (en) 1996-02-05 1998-05-07 Farmigea Spa VISCOSIZED OPHTHALMIC SOLUTIONS WITH TAMARIND GUM POLYSACCHARIDES
GB9603146D0 (en) 1996-02-15 1996-04-17 Innovative Tech Ltd Hydrogels
JP3989054B2 (en) 1996-07-29 2007-10-10 株式会社メニコン Cleaning material for contact lenses
JPH10221654A (en) 1997-02-07 1998-08-21 Seiko Epson Corp Solution for contact lens
EP0999825B1 (en) * 1997-07-29 2003-10-01 Alcon Laboratories, Inc. Ophthalmic compositions containing galactomannan polymers and borate
DK0999854T3 (en) * 1997-07-29 2004-02-09 Alcon Mfg Ltd Interchangeable viscoelastic systems containing galactomannan polymers and borates
JP3361106B2 (en) * 1997-07-29 2003-01-07 アルコン ラボラトリーズ，インコーポレイテッド Conditioning solution for hard contact lens care
CA2545947A1 (en) * 2003-12-11 2005-07-07 Alcon, Inc. Ophthalmic compositions containing a polysaccharide/borate gelling system

Also Published As

Publication number Publication date
DE69818675T2 (en) 2004-07-29
DE69839355T2 (en) 2009-06-04
US6403609B1 (en) 2002-06-11
TWI233801B (en) 2005-06-11
ES2302881T3 (en) 2008-08-01
CN1544092A (en) 2004-11-10
AR013272A1 (en) 2000-12-13
DK1348427T3 (en) 2008-06-30
CN1302201A (en) 2001-07-04
US20020183280A1 (en) 2002-12-05
CN1762381A (en) 2006-04-26
CY2013040I1 (en) 2015-11-04
HK1026618A1 (en) 2000-12-22
US20030206970A1 (en) 2003-11-06
EP0999825A1 (en) 2000-05-17
KR20010022286A (en) 2001-03-15
JP2003528797A (en) 2003-09-30
US20050075313A1 (en) 2005-04-07
HK1055392A1 (en) 2004-01-09
CN100408100C (en) 2008-08-06
BR9811574B1 (en) 2010-11-30
JP2007197461A (en) 2007-08-09
US7169767B2 (en) 2007-01-30
US6838449B2 (en) 2005-01-04
TW577751B (en) 2004-03-01
DE69839355D1 (en) 2008-05-21
WO1999006023A1 (en) 1999-02-11
LU92301I2 (en) 2013-12-31
ATE250923T1 (en) 2003-10-15
CY2013040I2 (en) 2015-11-04
US6486138B1 (en) 2002-11-26
EP0999825B1 (en) 2003-10-01
US6583124B2 (en) 2003-06-24
JP4673339B2 (en) 2011-04-20
CN1762381B (en) 2012-07-11
EP1348427B1 (en) 2008-04-09
ES2206965T3 (en) 2004-05-16
KR100507984B1 (en) 2005-08-17
PT999825E (en) 2004-02-27
AU737442B2 (en) 2001-08-16
CA2296080C (en) 2005-02-01
ATE391492T1 (en) 2008-04-15
AU8570598A (en) 1999-02-22
BR9811574A (en) 2000-08-29
DK0999825T3 (en) 2004-02-09
JP3979783B2 (en) 2007-09-19
DE69818675D1 (en) 2003-11-06
CN1229110C (en) 2005-11-30
ZA986533B (en) 1999-02-05
US20070098677A1 (en) 2007-05-03
EP1348427A1 (en) 2003-10-01
CY1110365T1 (en) 2015-04-29
PT1348427E (en) 2008-05-26

Similar Documents

Publication Publication Date Title
CA2296080A1 (en) Ophthalmic compositions containing galactomannan polymers and borate
CA2154950A1 (en) Borate crosslinked fracturing fluid and method
PT1028707E (en) CONTROLLED LIBERATION OPHTHALMIC FORMULATIONS CONTAINING SOLUABLE MEDICATIONS IN WATER
CA2322579A1 (en) Gelling ophthalmic compositions containing xanthan gum
HUP9901714A3 (en) Polysaccharide gel composition
ES2145330T3 (en) GELIFIERS, FIRE FIGHTING GELS AND FIRE FIGURE GLASSES.
WO2000011971A3 (en) Fiber and vitamin-fortified beverage
CA2171999A1 (en) Pharmaceutical formulations in form of thixotropic gel
CA2220095A1 (en) Silica abrasive compositions
AU3661689A (en) Cholesterol-lowering combination compositions of guar gum and niacin
AU6772590A (en) Hair treatment composition
ES8801172A1 (en) Coated glass microbubbles.
AU6119190A (en) New cosmetic compositions containing chitosan and glucosamine
CA2304010A1 (en) Methods and compositions for whitening teeth
CA2301176A1 (en) Self-binding shearform compositions
ES2153884T3 (en) COSMETIC OR DERMATOLOGICAL COMPOSITION IN THE FORM OF A GELIFIED OIL CONTAINING A MIXTURE OF ESTEARIC HYDROXY-12 ACID OR DIALQUYLAMIDE OF THE N-LAUROILGLUTAMIC ACID AND OF A HYDROGEN STYRENE / ALCADIENE COPOLYMER.
IL108039A (en) Xanthan gelling agents
AU4408593A (en) Methods and activator compositions to disinfect lenses
AU1918895A (en) Solid cosmetic composition
CA2189436A1 (en) Oral hygiene composition
CA2095721A1 (en) Gel type compositions having improved oil control
EP0744171A4 (en) Dental composition for hypersensitive dentin
AU5980200A (en) Ophthalmic compositions in form of aqueous gels
AU5770798A (en) Cosmetic or dermatological composition in the form of a gel containing in a mixture an associative copolymer, surfactant and a conditioning agent
EP0208313A3 (en) Gelling agent

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20180717